

**FORM 51 – 102F3  
MATERIAL CHANGE REPORT**

**1. Name and Address of Company**

bioMmune Technologies Inc.  
1780 – 400 Burrard Street  
Vancouver, BC V6C 3A6

**2. Date of Material Change**

April 22, 2016

**3. News Release**

News release dated April 22, 2016 was disseminated through Marketwired and was filed via SEDAR the same day.

**4. Summary of the Material Change**

Biomune appoints Dr. Patrick Gray as new Chief Executive Officer and President.

**5. Full Description of the Material Change**

Vancouver, British Columbia, April 22, 2016 - bioMmune Technologies Inc. (“bioMmune” or the “Company”) (TSX.V:IMU), a company focused on harnessing the body’s immune system to fight cancer and autoimmune diseases, announces that Dr. Patrick W. Gray has been appointed to serve as Chief Executive Officer and President. Dr. Gray has worked in the biotechnology industry for the past 35 years with extensive experience in drug discovery at Genentech, ICOS, and MacroGenics. He also has previous executive experience as Chief Scientific Officer, CEO, and as member of Boards of Director. His previous drug discovery efforts led to the development of the Hepatitis B vaccine and multiple drugs (such as Interferon-gamma) and drug targets (CCR5 and PI3 Kinase p110delta). Former bioMmune CEO and President, Dr. Reinhard Gabathuler has resigned his positions to become Senior Vice-President of Business Development. In his new role, Dr. Gray will lead the company’s R&D programs and financing activities, whereas Dr. Gabathuler will lead the company’s partnering and business development activities. BioMmune anticipates increasing partnering efforts resulting from its progress in its oncology and immunology programs.

**6. Reliance on subsection 7.1(2) or (3) of National Instrument 51 – 102**

N/A

**7. Omitted Information**

N/A

**8. Executive Officer**

Dr. Patrick Gray, President and CEO

Phone: (206) 650-6575

**9. Date of Report**

April 28, 2016